Viemed Healthcare, Inc. financials

  1. Home
  2. Financials
  3. VMD
VMD CIK 0001729149

Source: EDGAR filings · Built 2026-06-02T04:19:21Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow 11.88M 980.00K 18.96M 4.81M 2.75M 22.07M
EBITDA 51.56M 43.27M 36.19M 23.88M 22.89M 36.36M
Working Capital 7.44M 15.55M 6.24M 20.88M 29.50M 24.16M
Net Debt 2.45M -10.67M -2.52M -16.22M -22.58M -23.35M
Gross Margin 57.52% 59.40% 61.63% 60.99% 62.71% 61.01%
Operating Margin 8.49% 7.98% 7.83% 5.94% 9.89% 20.40%
Net Margin 5.53% 5.02% 5.60% 4.48% 7.80% 24.01%
Return on Equity (ROE) 10.55% 8.57% 8.99% 6.41% 9.62% 38.60%
Return on Assets (ROA) 7.50% 6.36% 6.61% 5.32% 7.74% 28.01%
Current Ratio 1.18× 1.42× 1.19× 2.11× 2.66× 2.05×
Debt-to-Equity 0.11× 0.05× 0.09× 0.01× 0.06× 0.09×
Effective Tax Rate 29.36% 29.44% 28.82% 30.79% 27.01% -19.60%
Cash Conversion Ratio 3.48× 3.47× 4.41× 4.46× 2.46× 1.11×
Accruals Ratio -0.19× -0.16× -0.23× -0.18× -0.11× -0.03×
SBC % of Revenue 3.38% 2.80% 3.20% 3.75% 4.40% 3.72%
CapEx Coverage 1.30× 1.03× 1.72× 1.21× 1.14× 2.69×
Free Cash Flow Per Share $0.29 $0.02 $0.47 $0.12 $0.07 $0.54

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/E Trailing (Diluted) 20.08× 28.64× 31.40× 47.25× 23.73× 9.95×
P/FCF 25.53× 334.17× 16.72× 62.58× 77.22× 14.25×
FCF Yield 3.92% 0.30% 5.98% 1.60% 1.29% 7.02%
EV / EBITDA 5.53× 7.01× 8.28× 11.37× 8.05× 7.72×
P/S 1.05× 1.40× 1.65× 2.07× 1.77× 2.32×
P/B 2.00× 2.39× 2.65× 2.96× 2.18× 3.72×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenues 270.28M 224.26M 183.01M 138.83M 117.06M 131.31M
Cost of Goods and Services Sold 114.82M 91.05M 70.22M 54.15M 43.65M 51.20M
Gross Profit 155.46M 133.20M 112.78M 84.68M 73.41M 80.11M
Research and Development Expense 3.02M 3.07M 2.78M 2.70M 2.11M 1.08M
Selling, General and Administrative Expense 121.37M 106.20M 87.88M 68.16M 54.89M 52.83M
Operating Income (Loss) 22.95M 17.90M 14.33M 8.25M 11.58M 26.78M
Income Tax Expense (Benefit) 6.39M 4.76M 4.15M 2.77M 3.38M -5.17M
Net Income (Loss) Attributable to Parent 14.93M 11.27M 10.24M 6.22M 9.13M 31.53M
Earnings Per Share, Basic $0.38 $0.29 $0.27 $0.16 $0.23 $0.81
Weighted Average Number of Shares Outstanding, Basic 38.90M 38.75M 38.35M 38.66M 39.49M 38.74M
Earnings Per Share, Diluted $0.37 $0.28 $0.25 $0.16 $0.22 $0.78
Weighted Average Number of Shares Outstanding, Diluted 40.82M 40.81M 40.38M 39.81M 40.68M 40.53M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 13.50M 17.54M 12.84M 16.91M 28.41M 30.98M
Assets, Current 48.49M 52.88M 38.37M 39.74M 47.31M 47.17M
Assets 199.15M 177.07M 154.90M 117.04M 117.96M 112.56M
Liabilities, Current 41.06M 37.33M 32.12M 18.86M 17.81M 23.02M
Long-term Debt, Excluding Current Maturities 11.29M 3.59M 6.00M 0 4.31M 5.80M
Liabilities 55.63M 43.77M 41.00M 19.95M 23.14M 30.87M
Stockholders' Equity Attributable to Parent 141.54M 131.39M 113.89M 97.09M 94.82M 81.69M
Common Stock, Shares, Outstanding 38.02M 39.13M 38.51M 38.05M 39.64M 39.19M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities 51.92M 39.09M 45.21M 27.75M 22.49M 35.11M
Payments to Acquire Property, Plant, and Equipment 39.98M 37.77M 26.09M 22.90M 19.74M 13.04M
Net Cash Provided by (Used in) Investing Activities -50.17M -30.70M -52.11M -23.98M -19.75M -8.41M
Payments for Repurchase of Common Stock 13.22M 0 0 9.57M 0 0
Net Cash Provided by (Used in) Financing Activities -5.79M -3.69M 2.83M -15.27M -5.32M -9.07M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (VMD CIK 0001729149), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

SF

STIFEL FINANCIAL CORP

BOH

BANK OF HAWAII CORPORATION

IRM

IRON MOUNTAIN INC